VMD
Viemed Healthcare, Inc. (VMD) Business Model Analysis (2026)
Overall Score
Revenue Demand
Revenue base remains supported by a low EV/Sales multiple of 1.13x and revenue per share of 7.89.
No material change in demand trends was indicated this month.
Profitability Margins
Gross margin remains healthy at 57.2%, but net margin is still modest at 4.8%.
EBIT margin of 7.7% and EBITDA margin of 17.8% indicate acceptable operating leverage, though not exceptional.
Cash Flow Conversion
Free cash flow remains solid with a 11.68x EV/FCF multiple and 8.6% FCF yield.
Cash conversion is decent, with operating cash flow covering capex by 1.93x and a cash conversion cycle of 22.8 days.
Balance Sheet Capital Structure
Leverage remains very low, with net debt to EBITDA at 0.02x and debt to equity at 0.08x.
Liquidity is adequate with a current ratio of 1.13x and quick ratio of 1.02x.
Competitive Position
ROIC of 11.0% and ROE of 10.3% suggest a reasonable but not dominant competitive position.
High SG&A at 47.3% of revenue continues to weigh on operating efficiency.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Viemed Healthcare, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

